Vobramitamab duocarmazine is under clinical development by MacroGenics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vobramitamab duocarmazine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vobramitamab duocarmazine overview

Vobramitamab duocarmazine (MGC-018) is under development for the treatment of solid tumors such as triple negative breast cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, head and neck squamous cell carcinoma, metastatic castration-resistant prostate cancer (mCRPC), metastatic uveal melanoma, pancreatic cancer, hepatocellular carcinoma, renal cell carcinoma  and ocular melanoma. It acts by targeting cells expressing CD276 antigen (B7 Homolog 3 or B7-H3).  It is administered by intravenous route. The therapeutic candidate comprises of antibody-drug conjugate and it is being developed based on proprietary B7-H3 antibody and a duocarmycin-based linker payload drug technology.

MacroGenics overview

MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, breast and gastroesophageal cancers, type 1 diabetes, HIV, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.

For a complete picture of Vobramitamab duocarmazine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.